SynchNeuro, Inc.

Based in the US, SynchNeuro, Inc. specializes in advanced medical devices that enhance neurological health through innovative technologies for diagnosing and treating neurological disorders. SynchNeuro, Inc. was founded in 2021 and is located in Philadelphia, US.

The company focuses on developing medical device solutions for neurological health. The founder's history is not detailed, and there are no mentions of any previous companies. In August 2025, SynchNeuro, Inc. raised USD 3 million in seed funding led by investor Boomerang Ventures.

SynchNeuro specializes in advanced medical device solutions aimed at enhancing neurological health. The company's core offerings focus on innovative technologies that facilitate the diagnosis and treatment of neurological disorders. These products utilize cutting-edge computational neuroscience approaches, providing healthcare professionals with tools to better understand brain function and improve patient outcomes. SynchNeuro's devices are designed for use in various clinical settings, primarily targeting hospitals and specialized neurological clinics.

Their client base includes neurosurgeons, neurologists, and healthcare institutions in North America and select markets in Europe, where there is increasing demand for sophisticated neurological interventions. SynchNeuro operates on a B2B transaction model, primarily engaging with healthcare providers and institutions. Revenue is generated through the sale of their flagship medical devices, which are offered under subscription and purchasing agreements. Transactions typically involve direct sales to hospitals, with options for leasing or outright purchase, ensuring flexibility for their clients.

The pricing structure is designed to cater to the varying needs of healthcare facilities, allowing for both one-time purchases and recurring revenue through service agreements and device maintenance. The company's innovative solutions are critical in addressing the complexities of neurological health, aligning with their commitment to improving patient care. SynchNeuro plans to advance its electroencephalography-based technology for real-time monitoring of blood glucose and other key health indicators, utilizing the funding from the Seed round raised in August 2025. The company aims to expand its product offerings and is exploring new markets, particularly in North America and Europe, with targeted launches expected by late 2025.